Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,866,901
  • Shares Outstanding, K 157,522
  • Annual Sales, $ 1,094 M
  • Annual Income, $ -139,310 K
  • 60-Month Beta 1.76
  • Price/Sales 2.65
  • Price/Cash Flow 30.03
  • Price/Book 2.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.48
  • Number of Estimates 5
  • High Estimate 0.59
  • Low Estimate 0.43
  • Prior Year 0.17
  • Growth Rate Est. (year over year) +182.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.25 +1.36%
on 01/24/20
21.40 -18.29%
on 12/26/19
-3.82 (-17.95%)
since 12/24/19
3-Month
17.25 +1.36%
on 01/24/20
21.88 -20.09%
on 11/25/19
-2.01 (-10.33%)
since 10/24/19
52-Week
17.11 +2.19%
on 10/10/19
37.75 -53.68%
on 04/09/19
-15.60 (-47.14%)
since 01/24/19

Most Recent Stories

More News
Look for Shares of Alkermes Plc to Potentially Rebound after Yesterday's 4.48% Sell Off

Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $17.38 to a high of $18.46. Yesterday, the shares fell 4.5%, which took the trading range below the 3-day low of $18.12...

ALKS : 17.63 (-3.13%)
Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Alkermes (ALKS) closed at $19.99, marking a -0.05% move from the previous day.

ALKS : 17.63 (-3.13%)
Alkermes (ALKS) Gains As Market Dips: What You Should Know

Alkermes (ALKS) closed the most recent trading day at $19.52, moving +1.61% from the previous trading session.

ALKS : 17.63 (-3.13%)
Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020 at 9:00 a.m. PT (12:00...

JPM : 133.22 (-2.43%)
ALKS : 17.63 (-3.13%)
LGND vs. ALKS: Which Stock Is the Better Value Option?

LGND vs. ALKS: Which Stock Is the Better Value Option?

LGND : 88.53 (-1.57%)
ALKS : 17.63 (-3.13%)
Alnylam Stock Up More Than 61% YTD on Pipeline Progress

Shares of Alnylam (ALNY) rise on significant pipeline progress.

ALNY : 119.94 (+1.68%)
REGN : 345.18 (-3.20%)
ALKS : 17.63 (-3.13%)
INVA : 14.25 (-0.84%)
Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA

Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.

CHRS : 18.14 (-3.10%)
ALKS : 17.63 (-3.13%)
BDSI : 5.76 (-1.03%)
FLXN : 17.57 (-2.33%)
New Strong Buy Stocks for December 26th

New Strong Buy Stocks for December 26th

RAD : 12.29 (-2.31%)
INXN : 91.32 (+0.84%)
ICHR : 36.32 (-3.35%)
HELE : 183.47 (+0.01%)
ALKS : 17.63 (-3.13%)
Seattle Genetics Submits NDA to FDA for Tucatinib Combo

Seattle Genetics (SGEN) submits an NDA to the FDA for tucatinib in combination with Herceptin and Xeloda seeking approval to treat locally advanced/metastatic HER2-positive breast cancer.

RHHBY : 41.2300 (-2.74%)
AZN : 49.28 (-1.83%)
ALKS : 17.63 (-3.13%)
SGEN : 113.58 (-1.53%)
Alkermes Plc Set to Possibly Pullback After Yesterday's Rally of 1.09%

Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $21.12 to a high of $21.56. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $21.29...

ALKS : 17.63 (-3.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade ALKS with:

Business Summary

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication...

See More

Key Turning Points

2nd Resistance Point 18.80
1st Resistance Point 18.50
Last Price 17.63
1st Support Level 18.00
2nd Support Level 17.80

See More

52-Week High 37.75
Fibonacci 61.8% 29.87
Fibonacci 50% 27.43
Fibonacci 38.2% 24.99
Last Price 17.63
52-Week Low 17.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar